FDA Panel Backs Palovarotene for Ultra-Rare Bone Disorder

Despite lingering concerns over post hoc analyses, palovarotene won the support of an FDA panel as a treatment for abnormal bone growth due to fibrodysplasia ossificans progressiva (FOP).